Impact ledger
Ginkgo Bioworks Holdings, Inc. (DNA): the developments shaping its investment case
Follow the evidence affecting Ginkgo Bioworks Holdings, Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Ginkgo Bioworks Holdings, Inc. · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-25
Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine Adjuvants
Channel: Direct revenue generation from new contract, validation of platform technology, potential for future partnerships.
Bullish· 1-3m
2026-09-25 · 4 reports
Pfizer and NVIDIA Form $80M Joint Venture in AI Biopharma Platform CytoReason
Channel: Second-order effect: Validation of the broader AI-driven synthetic biology and biopharma platform market, potentially attracting more investment and partnerships.
Bullish· 1-3m
2026-09-25
Pfizer and NVIDIA invest $80M in CytoReason JV as vaccine AI funding tops $140M
Channel: Secured a significant contract ($31M) for AI-enabled adjuvant discovery, indicating strong demand for its platform and services in a growing sector.
Bullish· 1-3m
Event impact log
9 events mapped to DNA since 2026-09-19. Evidence through 2026-09-25.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-25 | Pfizer and NVIDIA Form $80M Joint Venture in AI Biopharma Platform CytoReason | Second-order effect: Validation of the broader AI-driven synthetic biology and biopharma platform market, potentially attracting more investment and partnerships. | Bullish | 1-3m | 0.40 |
| 2026-09-25 | Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine Adjuvants | Direct revenue generation from new contract, validation of platform technology, potential for future partnerships. | Bullish | 1-3m | 0.70 |
| 2026-09-25 | Pfizer and Nvidia Form $80M CytoReason AI Drug Discovery JV | Securing a significant contract for computational adjuvant design, validating its platform and contributing directly to revenue. | Bullish | 1-3m | 0.60 |
| 2026-09-25 | Pfizer and NVIDIA invest $80M in CytoReason JV as vaccine AI funding tops $140M | Secured a significant contract ($31M) for AI-enabled adjuvant discovery, indicating strong demand for its platform and services in a growing sector. | Bullish | 1-3m | 0.70 |
| 2026-09-25 | Pfizer and NVIDIA Form $80M Joint Venture in AI-Driven Vaccine Discovery | Increased investor attention and validation for AI-driven biotechnology and synthetic biology platforms, potential for higher valuations for companies in the sector. | Bullish | 1-3m | 0.40 |
| 2026-09-25 | Pfizer and NVIDIA Form $80M CytoReason Venture as Vaccine AI R&D Expands | Securing a significant new contract, demonstrating demand for its platform and contributing directly to revenue. | Bullish | 1-3m | 0.70 |
| 2026-09-20 | Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pact | Increased investor attention on synthetic biology and AI in drug discovery, competitive landscape implications. | mixed | 1-3m | 0.40 |
| 2026-09-19 | Twist Bioscience partners with Eli Lilly on TuneLab AI discovery | Increased competitive pressure in synthetic biology and biomanufacturing services, potential for market share shifts. | watch | 1-3m | 0.30 |
| 2026-09-19 | Twist Bioscience partners with Eli Lilly on AI-driven TuneLab drug discovery | Increased investor attention and validation for synthetic biology platforms, but also increased competitive pressure. | mixed | 1-3m | 0.30 |
Continue this research
Build your Ginkgo Bioworks Holdings, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the DNA entity page →